Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

NCT01402089 is registered in ClinicalTrials.gov with Markus Joerger as lead sponsor.

NCT NCT01402089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01402089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Lead sponsor
Markus Joerger
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2012
Completion date
November 30, 2015
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stroma tumor, non small-cell lung cancer, renal-cell cancer